clarithromycin + lenalidomide + dexamethasone

The combination of clarithromycin, lenalidomide, and dexamethasone—commonly referred to as the BiRd regimen—is a multi-agent therapy primarily used in the treatment of multiple myeloma. Clarithromycin is a macrolide antibiotic with additional immunomodulatory properties; it may enhance the efficacy of glucocorticoids and immunomodulatory drugs through pharmacokinetic interactions and direct antineoplastic effects. Lenalidomide is an immunomodulatory agent that inhibits tumor necrosis factor-alpha (TNF-α), modulates cytokine production, enhances T-cell and natural killer cell activity, and has antiangiogenic properties. Dexamethasone is a synthetic glucocorticoid with potent anti-inflammatory and cytotoxic effects on lymphoid cells. The addition of clarithromycin to lenalidomide plus dexamethasone has been shown to improve response rates in newly diagnosed multiple myeloma patients compared to standard regimens[1][2][5]. The precise mechanism by which clarithromycin augments this combination remains under investigation but likely involves both immune modulation and increased steroid exposure[6].

Brand names

Biaxin (clarithromycin)Revlimid (lenalidomide)Decadron (dexamethasone)

Other names

clarithromycin + lenalidomide + dexamethasoneBiRd regimen